Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT ID: NCT00366249

Last Updated: 2010-04-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1061 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infections Diabetic Foot Osteomyelitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type ACTIVE_COMPARATOR

Tigecycline

Intervention Type DRUG

150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis

B

Group Type ACTIVE_COMPARATOR

Ertapenem

Intervention Type DRUG

Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tigecycline

150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis

Intervention Type DRUG

Ertapenem

Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 18 or older with diabetes and a qualifying foot infection. People with evidence of a diabetic foot infection with osteomyelitis may qualify for the osteomyelitis substudy arm.

Exclusion Criteria

* People with additional significant disease, infection with resistant pathogens, contraindication, or hypersensitivity to any test article or related antibiotic.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wyeth

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Belgium, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Hungary, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Spain, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Taiwan, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For South Africa, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Canada, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Australia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Austria, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Croatia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Latvia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Lithuania, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Romania, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Argentina, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Brazil, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Chile, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Mexico, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Sweden, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Germany, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Denmark, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Estonia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Finland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For France, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For UK/Great Britian: [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Switzerland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Greece, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Italy, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Poland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Russia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Slovakia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Turkey, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Ukraine, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For China, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Los Angeles, California, United States

Site Status

Los Angeles, California, United States

Site Status

Northridge, California, United States

Site Status

San Francisco, California, United States

Site Status

Sylmar, California, United States

Site Status

Torrance, California, United States

Site Status

Orlando, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

Pensacola, Florida, United States

Site Status

West Palm Beach, Florida, United States

Site Status

Honolulu, Hawaii, United States

Site Status

Chicago, Illinois, United States

Site Status

Evanston, Illinois, United States

Site Status

North Chicago, Illinois, United States

Site Status

Springfield, Illinois, United States

Site Status

Springfield, Illinois, United States

Site Status

Baltimore, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Somers Point, New Jersey, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Lima, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

West Reading, Pennsylvania, United States

Site Status

Columbia, South Carolina, United States

Site Status

Dallas, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Buenos Aires, Buenos Aires, Argentina

Site Status

Chivilcoy, Buenos Aires, Argentina

Site Status

Ciudadela, 3 de Febrero, Buenos Aires, Argentina

Site Status

Ciudadela, 3 de Febrero, Buenos Aires, Argentina

Site Status

La Plata, Buenos Aires, Argentina

Site Status

La Plata, Buenos Aires, Argentina

Site Status

La Plata, Buenos Aires, Argentina

Site Status

Loma Hermosa, Buenos Aires, Argentina

Site Status

Loma Hermosa, Buenos Aires, Argentina

Site Status

Mar del Plata, Buenos Aires, Argentina

Site Status

Merlo, Buenos Aires, Argentina

Site Status

Morón, Buenos Aires, Argentina

Site Status

Paraná, Entre Ríos Province, Argentina

Site Status

Paraná, Entre Ríos Province, Argentina

Site Status

Tunuyán, Mendoza Province, Argentina

Site Status

Rosario, Santa Fe Province, Argentina

Site Status

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Buenos Aires, , Argentina

Site Status

Buenos Aires, , Argentina

Site Status

Buenos Aires, , Argentina

Site Status

Buenos Aires, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Mendoza, , Argentina

Site Status

Melbourne, Victoria, Australia

Site Status

Melbourne, Victoria, Australia

Site Status

Vienna, , Austria

Site Status

Bornem, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Pellenberg, , Belgium

Site Status

Rio de Janeiro, , Brazil

Site Status

São Paulo, , Brazil

Site Status

Vancouver, British Columbia, Canada

Site Status

Winnipeg, Manitoba, Canada

Site Status

Hamilton, Ontario, Canada

Site Status

Ottawa, Ontario, Canada

Site Status

Chicoutimi, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Sherbrooke, Quebec, Canada

Site Status

Trois-Rivières, Quebec, Canada

Site Status

Santiago, , Chile

Site Status

Valdivia, , Chile

Site Status

Harbin, Heilongjiang, China

Site Status

Beijing, , China

Site Status

Beijing, , China

Site Status

Guangzhou, , China

Site Status

Tianjin, , China

Site Status

Bogotá, , Colombia

Site Status

Bogotá, , Colombia

Site Status

Zadar, , Croatia

Site Status

Zagreb, , Croatia

Site Status

Zagreb, , Croatia

Site Status

Odense, , Denmark

Site Status

Kohtla-Järve, Ida-Virumaa, Estonia

Site Status

Tallinn, , Estonia

Site Status

Tartu, , Estonia

Site Status

Tartu, , Estonia

Site Status

Kuopio, , Finland

Site Status

Turku, , Finland

Site Status

Strasbourg, , France

Site Status

Tourcoing, , France

Site Status

Giessen, Hesse, Germany

Site Status

Bochum, North Rhine-Westphalia, Germany

Site Status

Gelsenkirchen, North Rhine-Westphalia, Germany

Site Status

Rheine, North Rhine-Westphalia, Germany

Site Status

Münster, Northrhien-Westphalia, Germany

Site Status

Athens, , Greece

Site Status

Holargos, Athens, , Greece

Site Status

Rio-Patras, , Greece

Site Status

Budapest, , Hungary

Site Status

Budapest, , Hungary

Site Status

Budapest, , Hungary

Site Status

Debrecen, , Hungary

Site Status

Győr, , Hungary

Site Status

Kistarcsa, , Hungary

Site Status

Székesfehérvár, , Hungary

Site Status

Vadodara, Gujarat, India

Site Status

Bangalore, Karnataka, India

Site Status

Pune, Maharashtra, India

Site Status

Jaipur, Rajasthan, India

Site Status

Abano Terme (PD), , Italy

Site Status

Pisa, , Italy

Site Status

Rome, , Italy

Site Status

Liepāja, , Latvia

Site Status

Riga, , Latvia

Site Status

Riga, , Latvia

Site Status

Riga, , Latvia

Site Status

Riga, , Latvia

Site Status

Riga, , Latvia

Site Status

Kaunas, , Lithuania

Site Status

Kaunas, , Lithuania

Site Status

Kaunas, , Lithuania

Site Status

Klaipėda, , Lithuania

Site Status

Panevezys, , Lithuania

Site Status

Šiauliai, , Lithuania

Site Status

Vilnius, , Lithuania

Site Status

Vilnius, , Lithuania

Site Status

Colonia El Ritiro, Guadalajara, Mexico

Site Status

Guadalajara, Jalisco, Mexico

Site Status

Mendoza, Mendoza, Mexico

Site Status

Santa Fe, Santa Fe, Mexico

Site Status

Hermosillo, Sonora, Mexico

Site Status

Durango, , Mexico

Site Status

San Luis Potosí City, , Mexico

Site Status

San Luis Potosí City, , Mexico

Site Status

Veracruz, , Mexico

Site Status

Panama City, , Panama

Site Status

Lima, , Peru

Site Status

Lima, , Peru

Site Status

Bielsko-Biala, , Poland

Site Status

Cieszyn, , Poland

Site Status

Gdansk, , Poland

Site Status

Lodz, , Poland

Site Status

Warsaw, , Poland

Site Status

Wroclaw, , Poland

Site Status

Lisbon, , Portugal

Site Status

Lisbon, , Portugal

Site Status

Bacau, , Romania

Site Status

Bucharest, , Romania

Site Status

Cluj-Napoca, , Romania

Site Status

Lasi, , Romania

Site Status

Chelyabinsk, , Russia

Site Status

Kemerovo, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Nizhny Novgorod, , Russia

Site Status

Nizhny Novgorod, , Russia

Site Status

Novosibirsk, , Russia

Site Status

Omsk, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Smolensk, , Russia

Site Status

Yaroslavl, , Russia

Site Status

Yekaterinburg, , Russia

Site Status

Banska.Bysterica, , Slovakia

Site Status

Banská Bystrica, , Slovakia

Site Status

Bratislava, , Slovakia

Site Status

Ľubochňa, , Slovakia

Site Status

Martin, , Slovakia

Site Status

Nitra, , Slovakia

Site Status

Nové Zámky, , Slovakia

Site Status

Port Elizabeth, Eastern Cape, South Africa

Site Status

Benoni, Gauteng, South Africa

Site Status

Pretoria, Gauteng, South Africa

Site Status

Gyeonggi-do, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Barcelona, , Spain

Site Status

Getafe Madrid, , Spain

Site Status

Granada, , Spain

Site Status

Madrid, , Spain

Site Status

Palma de Mallorca, , Spain

Site Status

Copenhagen, , Sweden

Site Status

Huddinge, , Sweden

Site Status

Uppsala, , Sweden

Site Status

Basel, , Switzerland

Site Status

Geneva, , Switzerland

Site Status

Tainan City, , Taiwan

Site Status

Taoyuan Hsien, , Taiwan

Site Status

Adana, , Turkey (Türkiye)

Site Status

Capa-Istanbul, , Turkey (Türkiye)

Site Status

Istanbul, , Turkey (Türkiye)

Site Status

Cherkassy, , Ukraine

Site Status

Dnipro, , Ukraine

Site Status

Kiev, , Ukraine

Site Status

Kyiv, , Ukraine

Site Status

Kyiv, , Ukraine

Site Status

Lviv, , Ukraine

Site Status

Vinnytsia, , Ukraine

Site Status

Zaporizhzhya, , Ukraine

Site Status

Wishaw, Lanarkshire, United Kingdom

Site Status

Birmingham, West Midlands, United Kingdom

Site Status

Birmingham, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Chile China Colombia Croatia Denmark Estonia Finland France Germany Greece Hungary India Italy Latvia Lithuania Mexico Panama Peru Poland Portugal Romania Russia Slovakia South Africa South Korea Spain Sweden Switzerland Taiwan Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Lauf L, Ozsvar Z, Mitha I, Regoly-Merei J, Embil JM, Cooper A, Sabol MB, Castaing N, Dartois N, Yan J, Dukart G, Maroko R. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014 Apr;78(4):469-80. doi: 10.1016/j.diagmicrobio.2013.12.007. Epub 2013 Dec 16.

Reference Type DERIVED
PMID: 24439136 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3074K5-319

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.